Shots:

• The 1st patient has been dosed in the P-III (PALISADE study) to evaluate the efficacy & safety of ARO-APOC3 (25/50mg) vs PBO in a ratio (2:1:2:1) in 60 adults with FCS for 56wks. Patients will continue in the OLE study after 12mos.
• The primary objective is to evaluate the change from baseline in triglycerides b/w ARO-APOC3 & PBO @10mos. Additionally, participants in the PBO group will switch to the active drugs during the extension study
• Under the collaboration with Ambry Genetics, Arrowhead provides no-cost genetic testing to patients at risk of severe HTG & FCS. ARO-APOC3 is RNAi therapeutic that inhibits APOC3 production & is being evaluated in multiple clinical studies

Ref: Businesswire | Image: Businesswire